HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

QGEN

Qiagen N.V. (NYSE)

Healthcare — Diagnostics & Research

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Buy 2.0 / 5 14 analysts
$39.13
+$0.03 (+0.08%)
Target: $43.96 (12.3%)
Sign in to add QGEN to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$8.07B
P/E Ratio (TTM)19.96
Forward P/E14.83
EPS (TTM)$1.96
Dividend Yield0.89%
Profit Margin19.16%
Revenue Growth1.80%
ROE11.93%
Debt/Equity50.04
Recommendation Buy 2.0
Analyst Target$43.96
Analysts14
Indexes NYSE

Technical Indicators

RSI (14)65.2
Beta0.66
SMA 20-
SMA 40-
52-Week High$57.82
52-Week Low$32.53
50-Day Avg$36.15
200-Day Avg$43.65
Avg Volume$2.28M
Volume$1.84M

Performance Analysis

BULLISH

QGEN shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 26% of its 52-week range.
+ RSI at 65.2 shows positive momentum.
~ Modest revenue growth of 1.8% year-over-year.
+ Wall Street consensus is "Buy" from 14 analysts.
+ Average analyst target of $43.96 implies 12.3% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:28 UTC

Back to Screener Export Report